AIM
MYOK

Acrospire Investment Management’s MyoKardia, Inc. Common Stock MYOK Stock Holding History

Acrospire Investment Management’s Portfolio MYOK Stock Details MYOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-506
Closed -$7K – 1769
2017
Q2 		$7K Sell
506
-399
-44% -$5.26K 0.01% 1902
2017
Q1 		$12K Buy
+905
New +$11.6K 0.01% 1834

Other funds holding MYOK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PFM Health Sciences
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
Cormorant Asset Management
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EcoR1 Capital
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acrospire Investment Management's MYOK Position: Q3 2017 in Review

Acrospire Investment Management sold out of MyoKardia, Inc. Common Stock (MYOK) in Q3 2017, closing a stake of 506 shares — an estimated $7K sold.

Acrospire Investment Management first reported a position in MYOK in Q1 2017 and held it in 2 quarters. The position peaked at $12K in Q1 2017. 115 funds tracked by Wall St. Rank hold MYOK as of Q3 2017.

  • Acrospire Investment Management reported no remaining MyoKardia, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 506 MyoKardia, Inc. Common Stock shares in Q3 2017, an estimated $7K.
  • Acrospire Investment Management first reported a position in MyoKardia, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Acrospire Investment Management's MyoKardia, Inc. Common Stock position peaked at $12K in Q1 2017.
  • 115 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017.